RxDoctor Payments Data

Harry Tsou, MD

Vascular & Interventional Radiology · Long Island City, NYNPI 1598792632

Payments from drug & device makers

What this record shows

This record is dominated by other: $15,000 of the $18,663 with a category attached, or 80.4%. Angiodynamics, Inc. accounts for 80.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $15,253 and has fallen 98.9% since, to $173 in 2025.

$18,663in general payments, 2019–2025

Across 41 payments — averaging $455.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$15K
  • Abbott$2K
  • Vasorum USA Inc.$419
  • Bard Peripheral Vascular, Inc.$254
  • Inari Medical, Inc.$226
  • Terumo Medical Corporation$214
  • plus $439 from 9 others

What the payments were for

  • Travel & lodging$7944%
  • Food & beverage$2,86915%
  • Other$15,00080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,663 in reported general payments places this provider in the 80th percentile of 306 vascular & interventional radiology providers in New York.

See all vascular & interventional radiology providers in New York

Medicare billing

Part B allowed, 2024
$201,994
Medicare patients
144
Services billed
1,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate53$425

Paid to pharmacies, not to this prescriber.

Other vascular & interventional radiology in Long Island City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →